Adma Biologics Inc. (NASDAQ:ADMA)’s share price shot up 5% during mid-day trading on Friday . The company traded as high as $6.89 and last traded at $6.70, with a volume of 53,375 shares traded. The stock had previously closed at $6.38.

Separately, Maxim Group reaffirmed a “buy” rating and set a $24.00 price target on shares of Adma Biologics in a research report on Thursday, March 24th.

The firm’s market cap is $86.34 million. The company has a 50 day moving average price of $6.84 and a 200-day moving average price of $6.39.

Adma Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Friday, May 13th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.06. On average, equities research analysts forecast that Adma Biologics Inc. will post ($1.03) EPS for the current year.

In other news, Director Jerrold B. Grossman bought 45,769 shares of the stock in a transaction on Tuesday, May 3rd. The stock was acquired at an average price of $6.50 per share, with a total value of $297,498.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Adam S. Grossman bought 200,000 shares of the stock in a transaction on Tuesday, May 3rd. The stock was purchased at an average cost of $6.50 per share, with a total value of $1,300,000.00. The disclosure for this purchase can be found here.

ADMA Biologics, Inc is a biopharmaceutical company that develops and manufactures specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. The company’s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.